A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

<p>Abstract</p> <p>Background</p> <p>Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardio...

Full description

Bibliographic Details
Main Authors: Turti Tatyana V, Baibarina Elena N, Degtiareva Elena A, Keshishyan Elena S, Lobzin Yurii V, Namazova-Вaranova Leyla S, Prodeus Andrey P, Gudkov Konstantin M, Kruglova Anna I, Schulz Gregory A, Notario Gerard F
Format: Article
Language:English
Published: BMC 2012-09-01
Series:BMC Research Notes
Subjects:
Bronchopulmonary dysplasia
Congenital heart disease
Immunoprophylaxis
Lower respiratory tract infection
Preterm infant
Online Access:http://www.biomedcentral.com/1756-0500/5/484

Internet

http://www.biomedcentral.com/1756-0500/5/484

Similar Items